EE05497B1 - Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha - Google Patents

Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Info

Publication number
EE05497B1
EE05497B1 EEP200100472A EEP200100472A EE05497B1 EE 05497 B1 EE05497 B1 EE 05497B1 EE P200100472 A EEP200100472 A EE P200100472A EE P200100472 A EEP200100472 A EE P200100472A EE 05497 B1 EE05497 B1 EE 05497B1
Authority
EE
Estonia
Prior art keywords
polypeptide
cram
polynucleotide
antibody
soluble
Prior art date
Application number
EEP200100472A
Other languages
English (en)
Estonian (et)
Inventor
Albert Imhof Beat
Aurrand-Lions Michel
Original Assignee
Rmf Dictagene S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmf Dictagene S.A. filed Critical Rmf Dictagene S.A.
Publication of EE200100472A publication Critical patent/EE200100472A/xx
Publication of EE05497B1 publication Critical patent/EE05497B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
EEP200100472A 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha EE05497B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (2)

Publication Number Publication Date
EE200100472A EE200100472A (et) 2002-12-16
EE05497B1 true EE05497B1 (et) 2011-12-15

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100472A EE05497B1 (et) 1999-03-11 2000-03-13 Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha

Country Status (22)

Country Link
US (3) US7393651B2 (de)
EP (2) EP2292761A1 (de)
JP (2) JP4836329B2 (de)
CN (2) CN100469878C (de)
AT (1) ATE500328T1 (de)
AU (1) AU782139B2 (de)
BR (1) BR0008915A (de)
CA (1) CA2362896C (de)
CZ (1) CZ303128B6 (de)
DE (1) DE60045681D1 (de)
EE (1) EE05497B1 (de)
ES (1) ES2361905T3 (de)
HU (1) HU229376B1 (de)
IL (1) IL145310A0 (de)
IS (1) IS2819B (de)
MX (1) MXPA01009110A (de)
NO (1) NO333085B1 (de)
NZ (1) NZ514091A (de)
PL (1) PL207994B1 (de)
RU (1) RU2244748C2 (de)
WO (1) WO2000053749A2 (de)
ZA (1) ZA200107283B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
ATE500328T1 (de) * 1999-03-11 2011-03-15 Merck Serono Sa Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (de) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
JP2010504955A (ja) 2006-09-28 2010-02-18 メルク セローノ ソシエテ アノニム 接合部接着分子ｃ（ｊａｍ−ｃ）結合化合物とその利用方法
PL2907827T3 (pl) 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CN101796188B (zh) * 2007-08-06 2014-10-29 诺松制药股份公司 Sdf-1结合核酸及其用途
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
EP3368074A2 (de) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anti-faktor-d-antikörper und -konjugate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000036102A2 (en) * 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
EP0973892A2 (de) * 1997-03-14 2000-01-26 Human Genome Sciences, Inc. 28 menschliche sekretierte proteine
EP0970111A2 (de) * 1997-03-21 2000-01-12 Genetics Institute, Inc. Sekretierte proteine und polynukleotide, die für diese kodieren
DE69837761T2 (de) 1997-08-01 2008-01-17 Serono Genetics Institute S.A. 5' ests für sekretierte proteine aus gehirngeweben
US20030082541A1 (en) * 1997-09-17 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (de) * 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR und relatierte V Domäne zur Herstellung eines Arzneimittels zur Vorbeugung oder Behandlung von HSV-1, HSV-2 und BHV Infektionen
ATE500328T1 (de) * 1999-03-11 2011-03-15 Merck Serono Sa Vaskuläre adhesionsmoleküle und modulierung ihrer funktion
US7642341B2 (en) * 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (de) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs

Also Published As

Publication number Publication date
JP4836329B2 (ja) 2011-12-14
HU229376B1 (en) 2013-11-28
MXPA01009110A (es) 2002-08-20
IS2819B (is) 2012-12-15
JP2010233572A (ja) 2010-10-21
ES2361905T3 (es) 2011-06-24
EP1163337A2 (de) 2001-12-19
US20100267649A1 (en) 2010-10-21
NZ514091A (en) 2004-01-30
ATE500328T1 (de) 2011-03-15
CA2362896A1 (en) 2000-09-14
US8143056B2 (en) 2012-03-27
EE200100472A (et) 2002-12-16
PL350417A1 (en) 2002-12-16
WO2000053749A2 (en) 2000-09-14
HUP0200606A2 (en) 2002-06-29
DE60045681D1 (de) 2011-04-14
CZ20013267A3 (cs) 2002-02-13
NO20014417L (no) 2001-11-12
US20050266426A1 (en) 2005-12-01
RU2244748C2 (ru) 2005-01-20
AU782139B2 (en) 2005-07-07
JP2002537837A (ja) 2002-11-12
US7393651B2 (en) 2008-07-01
CZ303128B6 (cs) 2012-04-18
NO20014417D0 (no) 2001-09-11
EP2292761A1 (de) 2011-03-09
ZA200107283B (en) 2002-12-24
HUP0200606A3 (en) 2004-11-29
CN1355843A (zh) 2002-06-26
CN1637019A (zh) 2005-07-13
IL145310A0 (en) 2003-01-12
PL207994B1 (pl) 2011-02-28
EP1163337B1 (de) 2011-03-02
IS6072A (is) 2001-09-10
CN100469878C (zh) 2009-03-18
AU4105100A (en) 2000-09-28
US20080274970A1 (en) 2008-11-06
WO2000053749A3 (en) 2000-12-14
HK1044169A1 (en) 2002-10-11
US7670826B2 (en) 2010-03-02
NO333085B1 (no) 2013-02-25
CA2362896C (en) 2012-07-31
BR0008915A (pt) 2002-04-09

Similar Documents

Publication Publication Date Title
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
ATE255902T1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
ATE431359T1 (de) Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
TR200202253T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
ATE132197T1 (de) Monoklonale antikörper
DE59101889D1 (de) Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie.
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
ATE115409T1 (de) Glykoprotein-hormonrezeptor-moleküle.
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
ATE301194T1 (de) Beta-defensine
ATE271125T1 (de) Neuartige tyrosinkinase
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
BR0007816A (pt) Fator de estimulação óssea
EP0832109A4 (de) Faktor-2, homolog zum fibroblasten-wachstumsfaktor und verfahren zu seiner anwendung
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
ATE262307T1 (de) Verwendung von goldlegierungen für konstruktionselemente in der dentaltechnik
NO940797L (no) Reseptorderivater som har bindingseter for human-rhinovirus

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
HE1A Change of address
MM4A Lapsed by not paying the annual fees

Effective date: 20180313